Daniel E Bauer

List of Publications by Year
in descending order

93 papers	8,685 citations	81743 39 h-index	54797 84 g-index
106 all docs	106 docs citations	106 times ranked	11143 citing authors

#	Article	IF	Citations
1	DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling. PLoS ONE, 2022, 17, e0263829.	1.1	6
2	Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat Î²-hemoglobinopathies. Molecular Therapy, 2022, 30, 2693-2708.	3.7	11
3	Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells. , 2022, 1, 271-284.		5
4	Motif-Raptor: a cell type-specific and transcription factor centric approach for post-GWAS prioritization of causal regulators. Bioinformatics, 2021, 37, 2103-2111.	1.8	5
5	Transcription factor competition at the Î³-globin promoters controls hemoglobin switching. Nature Genetics, 2021, 53, 511-520.	9.4	43
6	Editing GWAS: experimental approaches to dissect and exploit disease-associated genetic variation. Genome Medicine, 2021, 13, 41.	3.6	32
7	ZNF410 represses fetal globin by singular control of CHD4. Nature Genetics, 2021, 53, 719-728.	9.4	35
8	Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program. American Journal of Human Genetics, 2021, 108, 874-893.	2.6	28
9	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell, 2021, 28, 833-845.e5.	5.2	23
10	Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency. Blood Advances, 2021, 5, 2339-2349.	2.5	7
11	Clonal hematopoiesis in sickle cell disease. Blood, 2021, 138, 2148-2152.	0.6	29
12	Editing outside the body: ExÂvivo gene-modification for Î²-hemoglobinopathy cellular therapy. Molecular Therapy, 2021, 29, 3163-3178.	3.7	12
13	Human Genetic Diversity Alters Therapeutic Gene Editing Off-Target Outcomes. Blood, 2021, 138, 3993-3993.	0.6	0
14	Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits. Nature Genetics, 2020, 52, 1333-1345.	9.4	24
15	Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nature Biotechnology, 2020, 38, 883-891.	9.4	502
16	Therapeutic base editing of human hematopoietic stem cells. Nature Medicine, 2020, 26, 535-541.	15.2	196
17	Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell, 2020, 26, 896-909.e8.	5.2	57
18	BCL11A enhancerâ€“edited hematopoietic stem cells persist in rhesus monkeys without toxicity. Journal of Clinical Investigation, 2020, 130, 6677-6687.	3.9	54

#	Article	IF	Citations
19	ZNF410 Represses Fetal Globin By Devoted Control of CHD4/NuRD. Blood, 2020, 136, 1-1.	0.6	0
20	Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nature Genetics, 2019, 51, 1149-1159.	9.4	83
21	Production of foetal globin in adult monkeys. Nature Biomedical Engineering, 2019, 3, 857-859.	11.6	0
22	Editing aberrant splice sites efficiently restores Î²-globin expression in Î²-thalassemia. Blood, 2019, 133, 2255-2262.	0.6	57
23	Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics. Cancer Genetics, 2019, 237, 69-77.	0.2	6
24	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	7.7	70
25	CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML. Nature Chemical Biology, 2019, 15, 529-539.	3.9	71
26	Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine, 2019, 25, 776-783.	15.2	344
27	CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nature Biotechnology, 2019, 37, 224-226.	9.4	891
28	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392.	2.5	121
29	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21
30	DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways and protein complexes from CRISPR screens. Bioinformatics, 2019, 35, 1981-1984.	1.8	3
31	Emerging Genetic Therapy for Sickle Cell Disease. Annual Review of Medicine, 2019, 70, 257-271.	5.0	90
32	Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing. Blood, 2019, 134, 4632-4632.	0.6	6
33	Gene Editing ELANE in Human Hematopoietic Stem and Progenitor Cells Reveals Disease Mechanisms and Therapeutic Strategies for Severe Congenital Neutropenia. Blood, 2019, 134, 3-3.	0.6	8
34	Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell, 2018, 33, 386-400.e5.	7.7	99
35	Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments. Nature Protocols, 2018, 13, 946-986.	5.5	70
36	14q32 and let-7 microRNAs regulate transcriptional networks in fetal and adult human erythroblasts. Human Molecular Genetics, 2018, 27, 1411-1420.	1.4	25

#	Article	IF	Citations
37	Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell, 2018, 173, 430-442.e17.	13.5	328
38	Growing and Genetically Manipulating Human Umbilical Cord Blood-Derived Erythroid Progenitor (HUDEP) Cell Lines. Methods in Molecular Biology, 2018, 1698, 275-284.	0.4	31
39	Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. British Journal of Haematology, 2018, 180, 630-643.	1.2	107
40	Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass. Cell Stem Cell, 2018, 23, 775-776.	5.2	1
41	CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data. Nature Methods, 2018, 15, 992-993.	9.0	33
42	FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity. Journal of Biological Chemistry, 2018, 293, 19797-19811.	1.6	30
43	CRISPRO: identification of functional protein coding sequences based on genome editing dense mutagenesis. Genome Biology, 2018, 19, 169.	3.8	34
44	AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing. Bioinformatics, 2018, 34, i202-i210.	1.8	28
45	An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nature Biotechnology, 2018, 36, 977-982.	9.4	328
46	Genetic therapies for sickle cell disease. Seminars in Hematology, 2018, 55, 76-86.	1.8	32
47	Highly Efficient Therapeutic Gene Editing of BCL11A enhancer in Human Hematopoietic Stem Cells from ÄÝ-Hemoglobinopathy Patients for Fetal Hemoglobin Induction. Blood, 2018, 132, 3482-3482.	0.6	2
48	Transcriptional Signaling Centers Govern Human Erythropoiesis and Harbor Genetic Variations of Red Blood Cell Traits. Blood, 2018, 132, 1277-1277.	0.6	0
49	Rational Targeting of a NuRD Sub-Complex for Fetal Hemoglobin Induction Following Comprehensive in Situ Mutagenesis. Blood, 2018, 132, 2342-2342.	0.6	0
50	Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nature Genetics, 2017, 49, 625-634.	9.4	96
51	Quantitative assessment of timing, efficiency, specificity and genetic mosaicism of CRISPR/Cas9-mediated gene editing of hemoglobin beta gene in rhesus monkey embryos. Human Molecular Genetics, 2017, 26, 2678-2689.	1.4	32
52	Functional interrogation of non-coding DNA through CRISPR genome editing. Methods, 2017, 121-122, 118-129.	1.9	28
53	Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. Blood Cells, Molecules, and Diseases, 2017, 67, 155-168.	0.6	11
54	Technical considerations for the use of CRISPR/Cas9 in hematology research. Experimental Hematology, 2017, 54, 4-11.	0.2	18

#	Article	IF	Citations
55	Gene Therapy. Hematology/Oncology Clinics of North America, 2017, 31, xiii-xiv.	0.9	0
56	Erythropoietin signaling regulates heme biosynthesis. ELife, 2017, 6, .	2.8	36
57	An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. Journal of Clinical Investigation, 2017, 127, 3065-3074.	3.9	48
58	Genome-wide association study of red blood cell traits in Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos. PLoS Genetics, 2017, 13, e1006760.	1.5	53
59	Genome-Wide CRISPR/Cas9 Screen Reveals That the Dcps Scavenger Decapping Enzyme Is Essential for AML Cell Survival. Blood, 2017, 130, 782-782.	0.6	1
60	Forward genetic screen of human transposase genomic rearrangements. BMC Genomics, 2016, 17, 548.	1.2	13
61	Analyzing CRISPR genome-editing experiments with CRISPResso. Nature Biotechnology, 2016, 34, 695-697.	9.4	410
62	Strict in vivo specificity of the Bcl11a erythroid enhancer. Blood, 2016, 128, 2338-2342.	0.6	33
63	Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood, 2016, 127, 839-848.	0.6	138
64	A genome editing primer for the hematologist. Blood, 2016, 127, 2525-2535.	0.6	23
65	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer, 2016, 122, 3632-3640.	2.0	145
66	Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. Lancet, The, 2016, 387, 2554-2564.	6.3	73
67	Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science, 2016, 351, 285-289.	6.0	260
68	Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. Journal of Clinical Investigation, 2016, 126, 3868-3878.	3.9	129
69	Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9. Journal of Visualized Experiments, 2015, , e52118.	0.2	123
70	EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood, 2015, 126, 1930-1939.	0.6	76
71	Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression. Blood, 2015, 126, 2811-2820.	0.6	20
72	The mTORC1/4E-BP pathway coordinates hemoglobin production with <scp>L</scp> -leucine availability. Science Signaling, 2015, 8, ra34.	1.6	54

#	Article	IF	Citations
73	miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. Molecular Therapy, 2015, 23, 1465-1474.	3.7	101
74	Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Current Opinion in Genetics and Development, 2015, 33, 62-70.	1.5	94
75	Functional footprinting of regulatory DNA. Nature Methods, 2015, 12, 927-930.	9.0	123
76	BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015, 527, 192-197.	13.7	726
77	Mitochondrial Protein Kinase A Regulates Heme Biosynthesis. Blood, 2015, 126, 271-271.	0.6	1
78	Hematopoietic Stem Cells Develop in the Absence of Endothelial Cadherin 5 Expression. Blood, 2015, 126, 1165-1165.	0.6	0
79	Characterization of Genomic Deletion Efficiency Mediated by Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/Cas9 Nuclease System in Mammalian Cells*. Journal of Biological Chemistry, 2014, 289, 21312-21324.	1.6	309
80	Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN).. Journal of Clinical Oncology, 2014, 32, 6057-6057.	0.8	7
81	Optimization of Bcl11a Knockdown By miRNA Scaffold Embedded Shrnas Leading to Enhanced Induction of Fetal Hemoglobin in Erythroid Cells for the Treatment of Beta-Hemoglobinopathies. Blood, 2014, 124, 2150-2150.	0.6	8
82	An SCF-FBXW7 Ubiquitin Ligase Mediated Feedback Loop Facilitates GATA Factor Switching and Reinforces Commitment to Terminal Erythroid Maturation. Blood, 2014, 124, 245-245.	0.6	0
83	Erythroid Cells Adapt to L-Leucine Scarcity By Reducing Hemoglobin Production Via the mTORC1/4E-BP Pathway. Blood, 2014, 124, 2660-2660.	0.6	0
84	An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level. Science, 2013, 342, 253-257.	6.0	518
85	Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6518-6523.	3.3	189
86	Identification Of BCL11A Structure-Function Domains For Fetal Hemoglobin Silencing. Blood, 2013, 122, 435-435.	0.6	3
87	Sideroflexin 4 Deficiency Results In An Erythroid Differentiation Defect. Blood, 2013, 122, 3417-3417.	0.6	0
88	Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. Clinical Cancer Research, 2012, 18, 5773-5779.	3.2	323
89	Reawakening fetal hemoglobin: prospects for new therapies for the Î²-globin disorders. Blood, 2012, 120, 2945-2953.	0.6	154
90	Combinatorial Assembly of Developmental Stage-Specific Enhancers Controls Gene Expression Programs during Human Erythropoiesis. Developmental Cell, 2012, 23, 796-811.	3.1	183

#	Article	IF	Citations
91	Hematopoietic SIN Lentiviral Micro RNA-Mediated Silencing of BCL11A: Pre-Clinical Evidence for a Sickle Cell Disease Gene-Therapy Trial. Blood, 2012, 120, 753-753.	0.6	1
92	Update on fetal hemoglobin gene regulation in hemoglobinopathies. Current Opinion in Pediatrics, 2011, 23, 1-8.	1.0	92
93	Functional Evaluation of HbF-Associated Region of BCL11A Locus. Blood, 2011, 118, 2148-2148.	0.6	0